Cardlytics Q3 2023 Earnings Presentation
14
Q3 2023 results
Revenue
Billings (1)
Gross Profit
Adjusted contribution (¹)
Net (loss) income attributable to common stockholders
Net loss per share (EPS), diluted
Adjusted EBITDA (1)
(1)(2)
Adjusted EBITDA margin
Non-GAAP net income (loss) (¹)
Non-GAAP net income (loss) per share (¹)
Cardlytics MAUs (in millions)
Cardlytics ARPU
Three Months Ended
September 30,
2023
$79,005
116,430
35,849
42,861
(23,966)
($0.63)
$3,946
5.0%
$318
$0.01
162.5
$0.49
2022
$72,706
110,392
26,018
35,143
6,267
$0.19
($12,708)
(17.5%)
($16,549)
($0.50)
156.2
$0.47
%
8.7%
5.5%
37.8%
22.0%
n/a
n/a
n/a
n/a
n/a
n/a
4.0%
4.3%
(Amounts in thousands, except MAUS and per share amounts)
Nine Months Ended
September 30,
2023
$220,036
321,480
90,888
111,338
(33,866)
($0.95)
($6,218)
(2.8%)
($857)
($0.02)
160.2
$1.37
2022
$216,039
316,361
79,223
103,043
(86,985)
($2.60)
($39,030)
(18.1%)
($50,571)
($1.51)
153.8
$1.40
%
1.9%
1.6%
14.7%
8.1%
(61.1%)
(63.5%)
(84.1%)
(84.4%)
(98.3%)
n/a
4.2%
(1) Billings, adjusted contribution, adjusted EBITDA, non-GAAP net loss and non-GAAP net loss per share are non-GAAP measures. Reconciliations of these non-GAAP measures to the most comparable GAAP measures are included in the
appendix to this presentation, as well as definitions of these non-GAAP terms.
(2) Adjusted EBITDA margin is calculated as adjusted EBITDA divided by revenue.
(2.14%)View entire presentation